Isomorphic Labs announced on November 17 that it has closed a $5 billion Series C, co-led by Greenoaks and Sequoia Capital, with a16z and several undisclosed new investors participating and Alphabet again putting in a large sum. Existing backers Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI fund all followed on, and the company says the round was oversubscribed.
The company was spun out of DeepMind in 2021 and is still led by CEO Demis Hassabis. It is headquartered in London, with offices in Cambridge, Massachusetts, and Lausanne, Switzerland. The round comes just six months after its $2.1 billion Series B.
Where the money is going
According to the company's press release, the funds have three main destinations:
- Continued development of its in-house drug design engine, IsoDDE, a foundation simulation model that spans multiple therapeutic areas and drug modalities and works with the company's own agents to reason about complex biological systems;
- Advancing its internal and partnered drug candidate pipeline, and building a partner network to study the mechanistic biology behind disease;
- Building "AI-first" translational medicine and clinical development infrastructure to move candidates into clinical trials.
The release says the internal oncology and immunology programs, as well as partnered programs, have produced positive preclinical results and are "ready for the clinic." Hassabis framed the round as helping the company push its first therapeutic programs into clinical trials:
"driving our first therapeutic programs towards clinical trials to deliver tangible impact for patients."
Read another way, five years after its founding, Isomorphic still has no drug in human trials. Reports in early November said the first clinical trials were expected to start before the end of 2026; this press release gives no date at all.
How much the company has raised
Adding up the publicly disclosed rounds: a $600 million first outside round in March 2025, a $2.1 billion Series B in May 2026, and now a $5 billion Series C, for a total of roughly $7.7 billion, more than 60% of which arrived in this round.
Put it in the context of the sector. CNBC, citing Dealroom data, reports that funding for drug discovery startups hit a record $23.2 billion in 2026. By a rough calculation, this $5 billion round equals a little over a fifth of that figure. The reports do not say whether Dealroom's tally already includes this round, so the ratio should be treated as a reference point only.
Valuation is the other blank. Reports in early November said Isomorphic was in talks on a round of about $5 billion at a valuation of about $50 billion. This time the company declined to disclose a valuation. On the reported numbers, investors would be buying roughly a tenth of the company, though there is no official figure to check that against.
Hassabis's position
According to CNBC, Hassabis stepped down as CEO of Google DeepMind about three and a half months ago, and his public role since then has been mainly as founder and CEO of Isomorphic. The other leader named is president Max Jaderberg, who said in the release that the models are delivering "repeatable scientific progress every week."
Large-model companies are also moving into drug research. OpenAI partnered with Novo Nordisk in April this year, and Anthropic launched its own AI drug discovery program in June. Isomorphic's approach is to design its own molecules and push its own pipeline, and in early 2024 it also signed collaborations with Eli Lilly and Novartis. With the money in hand, what outsiders will be watching is when the first clinical trial application gets filed.
Sources: Isomorphic Labs press release, CocoLoop, CNBC, Bloomberg, pharmaphorum. Funding amounts and investors follow the company's press release; the sector-wide funding total uses Dealroom's methodology; the valuation is a figure reported by media and has not been confirmed by the company.